2型糖尿病患者皮下脂肪面积与空腹C肽水平的相关性研究

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (675 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the characteristics and correlation between subcutaneous fat area and fasting C peptide level in patients with type 2 diabetes mellitus. Methods A total of 1461 patients with type 2 diabetes mellitus who admitted to the Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University from October 2017 to November 2019 were included. They were divided into three groups according to subcutaneous fat area, namely T1 group < 173.5 cm2, 173.5 cm2 ≤T2 group < 223.5 cm2, and T3 group ≥ 223.5 cm2. There were 506 cases in T1 group, 482 cases in T2 group and 473 cases in T3 group. The clinical indicators of height, weight, waist circumference and fasting C peptide level and other related indices were compared among three groups. Correlation analysis was used to analyze the correlation between fasting C peptide level and body fat, metabolic index, and multiple regression model was used to analyze the independent influencing factors of fasting C peptide level. Results There were no statistically significant differences between three groups in the levels of gender, glycosylated hemoglobin, fasting blood glucose, total cholesterol, low density lipoprotein cholesterin and the indicator of estimated glomerular filtration rate (P ＞ 0.05). Compared with T2 group, the age of T3 group was younger, with statistically significant difference (P ＜ 0.05), while the age of T1 group and T2 group was not statistically significant difference (P ＞ 0.05). Compared with T1 group, the indicators of body mass index, waist circumference, visceral fat area, diastolic blood pressure and uric acid were increased in T2 group and T3 group, while T3 group was higher than T2 group, the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Comparison of fasting C peptide levels between the three groups showed statistically significant differences (P ＜ 0.05). Correlation analysis showed that subcutaneous fat area were positively related with fasting C peptide level (r = 0.35, P ＜ 0.01)，and the two were still positively correlated after correction of age and diabetes course (r = 0.34, P ＜ 0.01). In multiple linear regression analysis, there was an independent positive correlation between subcutaneous fat area and fasting C-peptide level after correction for other confounding factors such as age, gender, visceral fat area, and glycosylated hemoglobin (B = 0.00, β = 0.16, P ＜ 0.01). Conclusion In patients with type 2 diabetes, fasting C peptide level increased with the increase of subcutaneous fat area, and the two show an independent positive correlation.

Key words： Type 2 diabetes mellitus Obesity Subcutaneous fat area Fasting C peptide level

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Simo KE Jing AN Yaxin ZHAO Dong

Cite this article:

LIU Simo KE Jing AN Yaxin ZHAO Dong. Correlation study between subcutaneous fat area and fasting C peptide level in patients with type 2 diabetes mellitus[J]. 中国医药导报, 2020, 17(18): 76-80,86.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I18/76

[1] Chan M. Obesity and diabetes：the slow-motion disaster [J]. Milbank Q，2017，95（1）：11-14.
[2] Smith U. Abdominal obesity：a marker of ectopic fat accumulation [J]. J Clin Invest，2015，125（5）：1790-1792.
[3] Xu L，Ma X，Verma NK，et al. Ablation of PPARγ in subcutaneous fat exacerbates age-associated obesity and metabolic decline [J]. Aging cell，2018，17（2）：e12721.
[4] Alberti KG，Zimmet PZ. Definition，diagnosis and classification of diabetes mellitus and its complications. Part 1： diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med，1998，15（7）：539-553.
[5] Elffers TW，de Mutsert R，Lamb HJ，et al. Body fat distribution，in particular visceral fat，is associated with cardiometabolic risk factors in obese women [J]. PLoS One，2017，12（9）：e0185403.
[6] Moon HU，Ha KH，Han SJ，et al. The association of adiponectin and visceral fat with insulin resistance and β-cell dysfunction [J]. J Korean Med Sci，2019，34（1）：e7.
[7] Sampath Kumar A，Arun Maiya G，Shastry BA，et al. Correlation between basal metabolic rate，visceral fat and insulin resistance among type 2 diabetes mellitus with peripheral neuropathy [J]. Diabetes Metab Syndr，2019，13（1）：344-348.
[8] Wang YW，Zhang JL，Jiao JG，et al. Physiological and metabolic differences between visceral and subcutaneous adipose tissues in Nile tilapia （Oreochromis niloticus） [J]. Am J Physiol Regul Integr Comp Physiol，2017，313（5）：R608-R619.
[9] Jialal I，Devaraj S. Subcutaneous adipose tissue biology in metabolic syndrome [J]. Horm Mol Biol Clin Investig，2018， 33（1）：/j/hmbci. 2018.33.issue-1/hmbci-2017-0074/hmbci-2017-0074.xml.
[10] Torre-Villalvazo I，Bunt AE，Alemán G，et al. Adiponectin synthesis and secretion by subcutaneous adipose tissue is impaired during obesity by endoplasmic reticulum stress [J]. J Cell Biochem，2018，119（7）：5970-5984.
[11] Saisho Y. Postprandial C-peptide to glucose ratio as a marker of β cell function： implication for the management of type 2 diabetes [J]. Int J Mol Sci，2016，17（5）：744.
[12] Luppi P，Drain P. C-peptide antioxidant adaptive pathways in β cells and diabetes [J]. J Intern Med，2017，281（1）：7-24.
[13] Cardellini M，Farcomeni A，Ballanti M，et al. C-peptide：A predictor of cardiovascular mortality in subjects with established atherosclerotic disease [J]. Diab Vasc Dis Res，2017，14（5）：395-399.
[14] Oliveira CM，Domingueti CP. The role of C-peptide in the attenuation of outcomes of diabetic kidney disease： a systematic review and meta-analysis [J]. J Bras Nefrol，2018，40（4）：375-387.
[15] Wahren J. C-peptide and the pathophysiology of microvascular complications of diabetes [J]. J Intern Med，2017， 281（1）：3-6.
[16] Pujia A，Gazzaruso C，Montalcini T. An update on the potential role of C-peptide in diabetes and osteoporosis [J]. Endocrine，2017，58（3）：408-412.
[17] Pinger CW，Entwistle KE，Bell TM，et al. C-Peptide replacement therapy in type 1 diabetes： are we in the trough of disillusionment? [J]. Mol Biosyst，2017，13（8）：1432-1437.
[18] Wahren J，Larsson C. C-peptide：new findings and therapeutic possibilities [J]. Diabetes Res Clin Pract，2015， 107（3）：309-319.
[19] He G，Pedersen SB，Bruun JM，et al. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects [J]. Horm Metab Res，2003，35（3）：178-182.
[20] Li H，Wu G，Fang Q，et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat [J]. Nat Commun，2018，9（1）：272.
[21] Cnop M，Landchild MJ，Vidal J，et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations：distinct metabolic effects of two fat compartments [J]. Diabetes，2002，51（4）：1005-1015.